news11 February 2020Da Volterra Announces Positive Top-line Results from a Phase 2 Clinical Trial Evaluating DAV132 in 260 Patients • First clinical study evaluating DAV132 in patients • Primary endpoint met: DAV132 was safe for use in…more
events03 February 2020Da Volterra’s CEO, Florence Séjourné, is attending BIO CEO in New York on Feb 10-11, 2020!The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded…more
events12 December 2019Da Volterra’s CEO, Florence Séjourné, and CBO, Pierre-Alain Bandinelli, are attending J.P. Morgan Healthcare Conference in SFO!The annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together…more
news03 December 2019Da Volterra Announces Positive Results of a Phase 1 Drug-Drug Interaction Study Demonstrating No Interaction Between DAV132 and Two Narrow Therapeutic Index DrugsParis (France), 3rd of December, 2019 – Da Volterra, a clinical-stage biopharmaceutical company developing innovative products to protect the intestinal…more
events31 October 2019Da Volterra attending World Anti-Microbial Resistance Congress in Washington DC on November 07-08!World Anti-Microbial Resistance Congress is the World largest AMR conference for all stakeholders combatting Anti-Microbial Resistance! The conference gathers global…more
events14 October 2019Da Volterra attending BIO-Europe in Hamburg on November 11-13!BIO-Europe’s world-class workshops, panels and active exhibition along with thousands of prescheduled one-to-one meetings make this event an unrivalled forum…more
events30 September 2019Da Volterra attending BioJapan 2019, Asia’s Premier Partnering Event for the Global Biotechnology Industry, on October 9-11 in Yokohama!BioJapan has played an important role in facilitating interaction between Japanese and global companies/organizations and stimulating new business opportunities for…more
events23 September 2019Da Volterra selected to attend TechShare 5th Edition, a unique Euronext educational programme to grow our Business!Da Volterra is proud to announce that it has been selected by Euronext among European fast-growing companies to take part…more
events16 September 2019Da Volterra attending CICON 2019 in Paris on Sept. 25-28!CICON 2019 is the 5th International Cancer Immunotherapy conference, the reference meeting for scientists, clinicians, regulators, drug developers, and patient…more
news03 July 2019Da Volterra Announces Completion of Patient Recruitment for its Phase 2 Clinical Study with DAV132, a Novel Microbiota Protective Therapy260 patients enrolled in the SHIELD Phase 2 study, first headline results expected by the end of the year 2…more
